Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy, safety, and quality of life (QOL) data when available, of adjuvant third‐generation AIs (anastrozole, letrozole, exemestane) compared to tamoxifen or placebo in postmenopausal women with early stage hormone receptor‐positive breast cancer.